FIGHT-302 is a multi-centre international study to evaluate the efficacy and safety of pemigatinib versus chemotherapy in unresectable or metastatic cholangiocarcinoma.
This study will compare chemotherapy (CisGem) with an FGFR-inhibitor in FGFR-altered patients and will require prior analysis of a tumour biopsy to determine that there is the appropriate FGFR-alteration.
Full Title: FIGHT-302: A Phase 3 Study of First-line Pemigatinib Versus Gemcitabine Plus Cisplatin for Cholangiocarcinoma With FGFR2 Fusions or Rearrangements.
This study is open and recruiting at the following UK locations:
- Aberdeen Royal Infirmary – Dr Ishtiag Zubairi
- Addenbrookes Hospital, Cambridge – Dr Bristi Basu
- The Royal Marsden, London – Dr Naureen Starling
- Hammersmith Hospital, London (Imperial College) – Dr Harpreet Wassan
- University College Hospital, London – Professor John Bridgewater
- Maidstone Hospital – Dr Justin Waters
- The Christie, Manchester – Dr Mairead McNamara
- University Hospital, Coventry – Dr Martin Scott Brown
- Velindre Cancer Centre, Cardiff – Dr Kein Yim
- St Vincent’s University Hospital, Dublin, Ireland – Professor Raymond McDermott
More details of the study, and European locations currently recruiting, can be found here:
https://bepartofresearch.nihr.ac.uk/ and search for Study: FIGHT-302
Incyte: https://www.incyte.comBack to previous page